drugset / Trial / NCT07516405
Safety and Tolerability Trial of Psilocybin in Healthy Older Adults
Phase 1
Recruiting
40 enrolled
University of Colorado, Denver
Dana-Farber Cancer Institute · collabEmory University · collabNYU Langone Health · collabNational Institute on Aging (NIA) · collabUniversity of California, San Francisco · collabUniversity of Nebraska · collab
NaSingle-groupOpen-labelTreatment
Summary
This study plans to learn more about the safety and tolerability of psychedelic administration (psilocybin) in healthy older adults ages 65-85.
Timeline
- Start
- 2026-04-01
- Primary completion
- 2028-03
- Completion
- 2028-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Psilocybin | Other / unclassified | 25 mg | Oral |
| Subject | Psilocybin | Other / unclassified | 30 mg | Oral |
Indications
No indication recorded.